Sigilon Therapeutics Stock News

Sigilon Therapeutics (NASDAQ:SGTX) had its price target cut by Morgan Stanley from $9.00 to $4.50 in a report issued on Tuesday, PriceTargets.com reports. They currently have an equal weight rating on the stock. Several other brokerages have also weighed in on SGTX. BTIG Research restated a buy rating and issued a $14.00 price objective on []

Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) have earned a consensus rating of Hold from the six analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month []

Sigilon Therapeutics Inc (NASDAQ: SGTX ) reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophilia A. The SIG-001 trial had been placed on FDA clinical hold following a serious adverse event report relating to the development of Full story available on Benzinga.com

Sigilon Therapeutics Inc (NASDAQ: SGTX) reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophi

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophilia A.

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) has been given an average rating of Buy by the six ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target []

Squarepoint Ops LLC lessened its holdings in shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) by 22.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 20,300 shares of the companys stock after selling 5,784 shares during the period. Squarepoint Ops LLCs holdings in Sigilon Therapeutics were worth $218,000 at []

Zacks Investment Research cut shares of Sigilon Therapeutics (NASDAQ:SGTX) from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, Sigilon Therapeutics Inc. is a biotechnology company. It seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform. The companys product candidates []

Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model

CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded L

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

A clinical hold for the company's lead candidate wasn't what investors wanted to hear this morning.

Galectin Therapeutics Inc. (NASDAQ: GALT) and Sigilon Therapeutics, Inc. (NASDAQ: SGTX) are among the biggest movers among biopharma stocks in early trading Friday. Galectin Spikes On Positive Data Fo

The FDA has instituted a clinical hold on Sigilon Therapeutics Inc's (NASDAQ: SGTX) Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A.  The clinical hold was in

The stock price of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) fell by over 20% pre-market. This is why it happened.